| Accession Number: | 0001209191-20-011258 |
| Date: | 2020-02-18 |
| Issuer: | NEKTAR THERAPEUTICS (NKTR) |
| Original Submission Date: |
LABRUCHERIE GIL M
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2020-02-18 | S | 5,938 | d | $22.35 | 253,221 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the rsus held by the reporting person. this sale is mandated by the issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| f2 | this transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. the price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the sec staff, the issuer, or a security holder of the issuer. |
| f3 | this number includes 997 shares held by the reporting person in the issuer's 401(k) plan and 4,218 shares held by the reporting person in the issuer's espp plan. the acquisition of these shares under both plans is exempt under rule 16b-3(c). |
